FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:780-788 March 11, 1999 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Attention-deficit–hyperactivity disorder (ADHD) is a common but controversial syndrome characterized by developmentally inappropriate hyperactivity, impulsivity, and inattention.¹ The disorder, which continues throughout life,^2,3,4,5,6,7 usually begins in childhood and is characterized by excessive activity, even when adjusted for developmental level, and limited behavioral control. A severely affected child, in whom behavioral control is absent, is exhausting to care for.

ADHD is controversial despite the acceptance of specific diagnostic criteria. That it is an extreme form of commonly occurring types of behavior rather than a disorder with discrete determinants is suggested by genetic studies, including a large study of twins, in which . . . [Full Text of this Article]

Prevalence

Genetics

Course

Treatment

Stimulant-Drug Preparations

Adverse Effects

Antidepressant Drugs

Alpha-Adrenergic–Agonist Drugs

Psychosocial Interventions

Other Treatments

Conclusions

Source Information

From the Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia, and the Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia (J.E.); the Department of Psychiatry, Division of Child and Adolescent Psychiatry, MCP–Hahnemann University, Philadelphia (P.J.A.); and the Child Psychiatry Branch, National Institute of Mental Health, Bethesda, Md. (J.L.R.).

Address reprint requests to Dr. Elia at the Children's Hospital of Philadelphia, Main Bldg., Rm. 3636, 34th St. and Civic Center Blvd., Philadelphia, PA 19104-4399.

References

This article has been cited by other articles:

• Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., for the SPD503 Study Group, (2008). A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Pediatrics 121: e73-e84 [Abstract] [Full Text]  
• Leslie, L. K., Wolraich, M. L. (2007). ADHD Service Use Patterns in Youth. J Pediatr Psychol 32: 695-710 [Abstract] [Full Text]  
• Nadkarni, S., LaJoie, J., Devinsky, O. (2005). Current treatments of epilepsy. Neurology 64: S2-S11 [Abstract] [Full Text]  
• Budson, A. E., Price, B. H. (2005). Memory Dysfunction. NEJM 352: 692-699 [Full Text]  
• Teo, S. K., Scheffler, M. R., Wu, A., Stirling, D. I., Thomas, S. D., Stypinski, D., Khetani, V. D. (2004). A Single-Dose, Two-Way Crossover, Bioequivalence Study of Dexmethylphenidate HCl with and without Food in Healthy Subjects. J Clin Pharmacol 44: 173-178 [Abstract] [Full Text]  
• Olfson, M., Gameroff, M. J., Marcus, S. C., Jensen, P. S. (2003). National Trends in the Treatment of Attention Deficit Hyperactivity Disorder. Am. J. Psychiatry 160: 1071-1077 [Abstract] [Full Text]  
• Miranda, A., Presentacion, M. J., Soriano, M. (2002). Effectiveness of a School-Based Multicomponent Program for the Treatment of Children with ADHD. J Learn Disabil 35: 547-563 [Abstract]  
• Guevara, J., Lozano, P., Wickizer, T., Mell, L., Gephart, H. (2002). Psychotropic Medication Use in a Population of Children Who Have Attention-Deficit/Hyperactivity Disorder. Pediatrics 109: 733-739 [Abstract] [Full Text]  
• Terry, A. V. Jr., Risbrough, V. B., Buccafusco, J. J., Menzaghi, F. (2002). Effects of ({+/-})-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride (SIB-1553A), a Selective Ligand for Nicotinic Acetylcholine Receptors, in Tests of Visual Attention and Distractibility in Rats and Monkeys. J. Pharmacol. Exp. Ther. 301: 284-292 [Abstract] [Full Text]  
• Guevara, J. P, Stein, M. T (2001). Evidence based paediatrics: Evidence based management of attention deficit hyperactivity disorder. BMJ 323: 1232-1235 [Full Text]  
• Schachter, H. M., Pham, B., King, J., Langford, S., Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165: 1475-1488 [Abstract] [Full Text]  
• Vitiello, B. (2001). Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. CMAJ 165: 1505-1506 [Full Text]  
• Jankovic, J. (2001). Tourette's Syndrome. NEJM 345: 1184-1192 [Full Text]  
• Poulin, C. (2001). Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ 165: 1039-1044 [Abstract] [Full Text]  
• Hill, P, Taylor, E (2001). Current topic: An auditable protocol for treating attention deficit/hyperactivity disorder. Arch. Dis. Child. 84: 404-409 [Abstract] [Full Text]  
• Markowitz, J. S., DeVane, C. L., Boulton, D. W., Nahas, Z., Risch, S. C., Diamond, F., Patrick, K. S. (2000). Ethylphenidate Formation in Human Subjects after the Administration of a Single Dose of Methylphenidate and Ethanol. Drug Metab. Dispos. 28: 620-624 [Abstract] [Full Text]  
• Ambrosini, P. J. (2000). A Review of Pharmacotherapy of Major Depression in Children and Adolescents. Psychiatr. Serv. 51: 627-633 [Abstract] [Full Text]  
• Volkow, N. D., Gatley, S. J., Fowler, J. S., Wang, G., Swanson;, J., Gainetdinov, R. R., Wetsel, W. C., Caron;, M. G. (2000). Serotonin and the Therapeutic Effects of Ritalin. Science 288: 11a-11 [Full Text]  
• Kent, M. A., Camfield, C. S., Camfield, P. R. (1999). Double-blind Methylphenidate Trials: Practical, Useful, and Highly Endorsed by Families. Arch Pediatr Adolesc Med 153: 1292-1296 [Abstract] [Full Text]  
• (1999). Genetics and Treatment of Uncomplicated ADHD. JWatch Neurology 1999: 16-16 [Full Text]